01407nas a2200193 4500008004100000245010200041210006900143260001300212300001000225490000600235520081800241653000801059653001601067653002301083653001801106653001901124100002501143856004501168 2022 eng d00aA Case Report on Bupivacaine Induced Limb Weakness; Type I Augmented Adverse Drug Reaction (ADR)0 aCase Report on Bupivacaine Induced Limb Weakness Type I Augmente cMay 2022 a18-190 v83 a
Bupivacaine is an amide-type, long-acting local anesthetic. It acts by preventing generation or conduction of nerve impulses by reducing sodium permeability and increasing action potential threshold. Lower limb motor weakness is a well-known complication of epidural analgesia with local anesthetics. In this case report a 60yr old female developed Bupivacaine induced lower limb weakness post-surgery. This event was identified as Type 1 augmented ADR which was assessed and reported with the help of Naranjo ADR scale. The dose of Bupivacaine was reduced as per clinical pharmacist’s suggestion and that helped in recovery from the weakness on the same day. Type 1 augmented ADR is related to the pharmacological action of the drug or due to the exaggerated pharmacologic response.
10aADR10aBupivacaine10aEpidural analgesic10aLimb weakness10aNaranjo scale.1 aJohn, Jeffin, Gloria uhttps://jppcm.org/article/2022/8/1/18-19